Bristol-Myers Squibb Co
BMY: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$26.00 | Xrvrv | Zwbhdlchw |
Bristol Faces Major Near-Term Patent Losses, but New Drugs Should Help Stabilize the Top Line
Business Strategy and Outlook
Adept at partnerships and acquisitions, Bristol-Myers Squibb has built a strong portfolio of drugs and a robust pipeline. This strategy is seen with its large acquisition of Celgene, which netted the firm an excellent pipeline and a strong entrenchment in blood cancer. We believe the strong overall pipeline helps support its wide moat.